The data isn’t published yet (presumably this was shown during the ASCO conference this weekend) but this is a bit misleading and the results seem underwhelming. The DFS numbers are not new and known, the reason this is in the news as it’s the first report of OS numbers from the initial ADAURA trial. I can’t be definitive without seeing the data yet but: 1. Osimertinib is not that new, in the context of curative inte…
Can you elaborate a bit on the cost? Why is it expensive? Will it still be expensive after the patents/marketing-exclusivity expires?
AstraZeneca’s patent expires in 2035 and as a cash cow ($2B in revenue) I would expect they continue to aggressively fight competitors in court.
Imatinib (the 1st gen drug of the same class) went generic a few years ago and is 99% cheaper now.
I assume we’ll see something similar with osimertinib but I can’t comment on whether there’s any secret sauce that makes it different.
Perhaps one of the pharma/biochem HN commenters can offer more insight.